Jan Medical Secures $7.5M Funding to Advance Nautilus BrainPulse 1100 for Neurological Disorder Diagnosis

Jan Medical, based in Mountain View, California, recently raised $7.5 million from Germany’s Brainlab to fund the research and development of connected devices for diagnosing neurological disorders. The device will aid in the detection of neurological conditions such as concussions and strokes. Reportedly, Jan Medical has raised at least $10.6 million for this project to date. The company will use these funds to complete various clinical trials and file for initial FDA approval and CE marking registration.

Jan Medical CEO Paul Lovoi’s wife, named Jan, passed away following a subarachnoid hemorrhagic stroke. After her death, Lovoi founded this medical company and named it after his wife.

“I have extensive knowledge about stroke. I founded this company to determine cerebrovascular pathology using a better method, without relying on the catheterization lab and angiography,” Lovoi told Mobi Health News. “That was my original intention in establishing this medical technology company.”

Although Lovoi began working at the company in 2003, he left midway and did not return to work full-time until 2008.

The diagnostic device developed by Jan Medical, named Nautilus BrainPulse 1100, consists of a headset, a data collector, a battery, and a touchscreen computer. The headset is equipped with two sensors: one for detecting heart rate and the other for monitoring ambient noise. It also features six accelerometers to measure head impact acceleration. The diagnostic test is administered by nurses working in neuro-intensive care and emergency departments, and it takes only three minutes to complete.

Lovoi stated that although the diagnostic device can currently be connected to a portable computer, his ultimate plan is to synchronize the headset with a tablet and store the data in the cloud.

To evaluate the performance of this diagnostic device, Jan Medical has been conducting experimental studies, with a primary focus on concussion. The company plans to recruit 600 to 800 participants who are either highly susceptible or less susceptible to concussions to complete the trial. By comparing BrainPulse readings between these two groups, it aims to assess the effectiveness of the Nautilus BrainPulse in diagnosing concussions.

The company plans to first apply for approval of the accuracy and safety of NautilusBrainPulse in detecting brain pulses, and then seek certifications related to neural spasms, ischemic stroke, and concussion.

Compiled by: Chen Kun